Denouncing the $557 billion industry as “horrible middlemen,” responsible for—and “rich as hell” from—America’s incomparably high prescription drug prices, Trump vowed to get rid of them. “We’re going to knock out the middlemen,” he said at a press conference at Mar-a-Lago.
Trump is hardly the first to go after PBMs. They make up an industry whose stated purpose is to help employers and other health care purchasers lower the cost of drugs, but for decades they’ve been accused of doing the opposite—and driving up spending through opaque, profit-driven pricing tactics.
Indeed, condemnation of PBMs is one of the rare points where Trump can find common cause with progressive lawmakers like Elizabeth Warren and activist regulators at Joe Biden’s Federal Trade Commission, which dropped a report just days before Trump’s inauguration accusing the biggest PBMs of price gouging. At a time when consumers’ frustration with the health care system has reached new peaks, taking on these little-understood players could give the government a bipartisan win with huge potential impact.
It’s little wonder that discontent with PBMs is so widespread. Americans spend more on medications than other countries—roughly twice as much per capita. By every measure, that spending is on the rise; by drug “list price,” the increase is astronomical—from $636 billion in 2018 to $917 billion in 2023. What exactly are PBMs saving us from, you might ask.
Employers and other health care payers despise PBMs' lack of transparency; pharmacies complain their high jinks are driving them out of business. Consumers may not know PBMs by name, but the drug-access and cost issues that frustrate and frighten them often stem from PBMs' decisions. More than half of U.S. adults worry about being able to afford prescription drugs; 30% couldn't afford them at some point last year.
Esta historia es de la edición February - March 2025 de Fortune US.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor ? Conectar
Esta historia es de la edición February - March 2025 de Fortune US.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor? Conectar
The Blackstone Edge
90 DAYS. DOZENS OF INTERVIEWS. BILLIONS ON THE LINE. HOW BLACKSTONE'S CEO-MAKER GETS THE JOB DONE.
When Elon Musk has a really tough job, he turns to Steve Davis. DOGE might do the same.
IT WAS THE FALL OF 2022 when employees at Elon Musk's Boring Company began to notice Steve Davis wasn't around.
ASK ANDY - SHOULD MY STARTUP RAISE MONEY FROM VCS? IF SO, WHICH ONES DO I CHOOSE?
A FRIEND—I’ll call him Allen—spent years bootstrapping his real estate enterprise software company. After a long struggle to get to $1 million in sales, his business recently surged to $10 million, and revenue is now growing 100% year on year.
ELLIOTT HILL - JUST DOING IT
Staffers and brand loyalists cheered when Nike's new CEO came out of retirement to lead the company he has had an “irrational love” for since he began there as an intern. Turning it around will take more than good vibes.
HOW TO PLAN YOUR NEXT $100,000 VACATION
ON AN EXCURSION to the ancient city of Petra, Jordan, clients helicoptered in after-hours so they could tour the ruins alone.
THE BATTLE OVER AG1
Influencers are fighting over it. Scientists scoff at it. But the $100-a-month powder once known as Athletic Greens is only getting more popular.
THE WORKPLACE - GEN ZERS WANT TO BE THEIR OWN BOSS.CAN THE CORPORATE WORLD WOO THEM BACK?
CHASE GALLAGHER WAS 12 years old when he started mowing his neighbors' lawns in Chester County, Pa., for $35 a pop in the summer of 2013. At first the Gen Zer had only two customers, but thanks to some aggressive leafleting, he had 10 clients by the following year.
How much can DOGE do?
Elon Musk and Donald Trump aim to cut as much as $2 trillion in federal spending. It'll be even harder than it sounds.
YOUNG PEOPLE ARE DRINKING LESS ALCOHOL. CAN CEO MICHEL DOUKERIS PERSUADE THEM TO KEEP DRINKING AB INBEV'S BEERS?
SOME TIME AGO, top CEOs at an invitation-only seminar at Harvard Business School were asked to imagine the four crises they would likely confront during their tenure at the top: a health emergency, a geopolitical conflict, an economic downturn, and a trade war.
America's drug middlemen are now a $557 billion industry. Can Trump and his allies 'knock out' PBMs?
IN LATE DECEMBER, President-elect Donald Trump put pharmacy benefit managers, or PBMs, on notice.
